Trials / Completed
CompletedNCT04211389
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 442 (actual)
- Sponsor
- Arcutis Biotherapeutics, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis
Detailed description
This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily x 8 weeks to subjects with psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ-151 0.3% cream | ARQ-151 0.3% cream |
| DRUG | ARQ-151 vehicle cream | ARQ-151 vehicle cream |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2020-11-23
- Completion
- 2020-11-23
- First posted
- 2019-12-26
- Last updated
- 2022-12-07
- Results posted
- 2022-10-18
Locations
39 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04211389. Inclusion in this directory is not an endorsement.